Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
444 participants
OBSERVATIONAL
2010-04-30
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute dyspnea in ED
Acute severe shortness of breath (SOB) in emergency Department (ED) with suspicion of acute heart failure (AHF) or Pulmonary Embolism (PE)or Community-acquired pneumonia (CAP) or acute Exacerbation of chronic obstructive pulmonary disease (AE COPD)
Prognostic value of Biomarkers
Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prognostic value of Biomarkers
Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis suspected: CAP, PE,EACOPD, AHF
Exclusion Criteria
* unreachable on Day 30
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ThermoFisher Scientific Brahms Biomarkers France
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre Hausfater, Pr
Role: STUDY_CHAIR
ED Pitié SalpêtrièreHospital in Paris
Yann-Erick Claessens, Dr
Role: PRINCIPAL_INVESTIGATOR
ED Cochin Hospital in Paris
Guillaume Der Sahakian, Dr
Role: PRINCIPAL_INVESTIGATOR
ED Hotel Dieu Hospital in Paris
Arnaud Martinage, Dr
Role: PRINCIPAL_INVESTIGATOR
ED Hotel Dieu Hospital in Nantes
Fatima Rayeh, Dr
Role: PRINCIPAL_INVESTIGATOR
ED La Miletrie Hospital in Poitiers
Eric Weil, Pr
Role: PRINCIPAL_INVESTIGATOR
ED Hospital B in Lille
Luc-Marie JOLY, Dr
Role: PRINCIPAL_INVESTIGATOR
ED Charles Nicolle Hospital in Rouen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emergency department of Pitié Salpetriere Hospital
Paris, Paris, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BIODINER BRAHMS France
Identifier Type: -
Identifier Source: org_study_id